<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02446353</url>
  </required_header>
  <id_info>
    <org_study_id>LG-ESCL001</org_study_id>
    <nct_id>NCT02446353</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety Study of Apetrol ES</brief_title>
  <acronym>Apetrol</acronym>
  <official_title>A Randomized, Open Label, Single Dose, Cross-over, Phase I Trial to Investigate Safety and Pharmacokinetics of Apetrol ES and Megace® Under Fasting and Fed Conditions in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Open Label, Single dose, Cross-over, Phase I Trial to Investigate Safety and
      Pharmacokinetics of Apetrol ES and Megace® in Healthy Male Volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      [Part 1] fasting [Part 2] fed
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Pre-dose(0h), 1, 2, 3, 4, 5, 6, (7), 8, 10, 12, 24, 48, 72, 96, 120 h</time_frame>
    <description>16 times(fasting), 15 times(fed)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>Pre-dose(0h), 1, 2, 3, 4, 5, 6, (7), 8, 10, 12, 24, 48, 72, 96, 120 h</time_frame>
    <description>16 times(fasting), 15 times(fed)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf, %AUCextra</measure>
    <time_frame>Pre-dose(0h), 1, 2, 3, 4, 5, 6, (7), 8, 10, 12, 24, 48, 72, 96, 120 h</time_frame>
    <description>16 times(fasting), 15 times(fed)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Pre-dose(0h), 1, 2, 3, 4, 5, 6, (7), 8, 10, 12, 24, 48, 72, 96, 120 h</time_frame>
    <description>16 times(fasting), 15 times(fed)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Pre-dose(0h), 1, 2, 3, 4, 5, 6, (7), 8, 10, 12, 24, 48, 72, 96, 120 h</time_frame>
    <description>16 times(fasting), 15 times(fed)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Megace : fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Megace / Apetrol ES : comparator / test, fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apetrol ES : fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apetrol ES / Megace : test / comparator, fed, cross-over</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Megace : fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Megace / Apetrol ES : comparator / test, fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apetrol ES : fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apetrol ES / Megace : test / comparator, fasting, cross-over</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apetrol ES / Megace</intervention_name>
    <description>Sequences of administered drugs</description>
    <arm_group_label>Megace : fed</arm_group_label>
    <arm_group_label>Apetrol ES : fed</arm_group_label>
    <arm_group_label>Megace : fasting</arm_group_label>
    <arm_group_label>Apetrol ES : fasting</arm_group_label>
    <other_name>Apetrol ES(ES81) 625 mg / 5mL, Megace 800mg / 20mL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is a healty male between 20 and 55 years old.

          -  In a ± 20% than ideal body weight. [ideal body weight(kg) = height(cm)-100) x 0.9
             (Broca's rule)

          -  Subjects who are considered to be suitable in conducting the clinical trial in serum
             test, hematology test, hemato-chemical test, urine test and 12-ECG result.

          -  Is willing and able to comply with scheduled visits, treatment plan, laboratory tests,
             and other study procedures.

          -  Agrees to use an adequate means of contraception during clinical trials

          -  Subject who has voluntarily decided to participate in this clinical trial and
             consented in writing.

        Exclusion Criteria:

          -  Is allergic against Megestrol acetate or other drugs (Aspirin, NSAIDs, Antibiotics,
             etc.) or against foods, or has an clinically serious allergic history.

          -  Subjects who have present condition or past history of any disease involving liver,
             kidney, nervous system, immune system, respiratory system, or endocrine system;
             hematologic and oncologic disease; cardiovascular disease; or psychiatric disorder
             (mood disorder, obsessive-compulsive disorder, etc. that may affect ADME of
             investigational medicinal products.

          -  In the vital signs measured in sitting position at the screening visit, subjects who
             have hypertension desease(a systolic blood pressure of ≥ 150 mmHg or a diastolic blood
             pressure of ≥ 100 mmHg).

          -  Diabetic patients or the patients who are abnormal of impaired glucose tolerance.

          -  The patients who have a history of Arterial Embolism.

          -  The patients who have a history of adrenal insufficiency like hypotension or nausea or
             vertigo or asthenia or etc.

          -  Subjects who have a history of drug abuse or shown positive reaction to drugs that may
             be abused from a urine drug screening

          -  Subjects who took any specialized drug or an herbal medication within 2 weeks before
             the date of first administration or took any over the counter (OTC) drug within 1 week
             (however, they may be included as subjects if appropriate depending on the
             investigator's discretion)

          -  Subjects who had whole blood donation within 2 months or component blood donation
             within 1 month before the clinical trial.

          -  Subjects who have abnormal diets that may affect ADME of investigational medicinal
             products.

          -  Subjects who have been drinking extremely alcohol and caffeine (more than caffeine 5
             cups/day, soju 3 cups/day, beer 3 cups/day, liquors 2 cups/day, 10 cigarettes/day) or
             can't refrain from drinking during the clinical trial period.

          -  Subjects who had administration a barbiturates within 1 month before the date of first
             drug administration

          -  Subjects who already participated in other clinical trials within 2 months before this
             clinical trial.

          -  Subjects who are considered to be unsuitable in conducting the clinical trial for
             other reason at the principal investigator's discretionary judgment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyungsoo Park, Ph D, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2015</study_first_submitted>
  <study_first_submitted_qc>May 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2015</study_first_posted>
  <last_update_submitted>May 13, 2015</last_update_submitted>
  <last_update_submitted_qc>May 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Male Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Megestrol Acetate</mesh_term>
    <mesh_term>Megestrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

